title: Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients.
abstract: OBJECTIVE
  Antibodies to oxidized low-density lipoproteins (oxLDLAbs) are detectable in the serum of patients with and without atherosclerosis, but it is unclear if they play a pathogenic or a protective role in atherogenesis or if they are simply a marker of atherosclerosis. Therefore, in a prospective cohort study we investigated if oxLDLAbs titer predicts cardiovascular (CV) events in high-risk coronary artery disease patients.
  
  
  RESULTS
  The titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins was measured in 748 randomly selected patients of the GENICA study who underwent coronary angiography and assessment of incident CV events at follow-up. Patients were classified by oxLDLAbs into a low and a high titer group, corresponding to the first three and the last quartile, respectively. Cardiovascular event-free survival was compared between oxLDLAbs groups by Kaplan-Meier and multivariate technique including propensity score matching analysis. During long-term follow-up (median 7.2 years) CV deaths were observed in 65 patients (11.6%), more commonly in the high than in the low oxLDLAbs group (patients free from CV death 83.1% vs. 89% respectively, p=0.025). The incidence of CV events was also higher in the former than in latter (event-free survival 69.2% vs. 77.7% respectively, p=0.030).
  
  
  CONCLUSIONS
  An oxLDLAbs titer above the 75th percentile is a marker of LDL oxidation which predicts a worse CV prognosis at long term follow-up in high-risk Caucasian patients referred for coronary angiography.
authors.affiliation: Dept. of Medicine-Internal Medicine University of Padua, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Maiolino
authors.forename: Luigi
authors.initials: L
authors.lastname: Pedon
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cesari
authors.forename: Anna Chiara
authors.initials: AC
authors.lastname: Frigo
authors.forename: Marlena
authors.initials: M
authors.lastname: Barisa
authors.forename: Giacomo
authors.initials: G
authors.lastname: Rossitto
authors.forename: Teresa Maria
authors.initials: TM
authors.lastname: Seccia
authors.forename: Mario
authors.initials: M
authors.lastname: Zanchetta
authors.forename: Gian Paolo
authors.initials: GP
authors.lastname: Rossi
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis / Q000401:mortality*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D007074:Immunoglobulin G; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D008315:Malondialdehyde
keywords: Anti-LDL-oxidized antibodies; Atherosclerosis; BP; CAD; Coronary artery disease; HDL; LDL; MDA; MI; OxLDL; OxLDLAbs; Prognosis; antibodies anti-oxidized low density lipoprotein; blood pressure; coronary artery disease; high-density lipoprotein; low density lipoprotein; malondialdehyde; myocardial infarction; oxidized low density lipoprotein